Please login to the form below

Not currently logged in
Email:
Password:

GRI

This page shows the latest GRI news and features for those working in and with pharma, biotech and healthcare.

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Ziylo could help it stay ahead in key insulin franchise. Novo Nordisk is aiming to develop the world’s first glucose responsive insulin (GRI) by acquiring UK biotech start-up Ziylo.

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    TiGenix’ board is backing the takeover deal, which values the company at 520m (around $630m), and two major shareholders - Gri-Cel and Grifols - have already said they will tender their shares.

  • No man is an island

    Perhaps the most high-profile example of these is the Global Reporting Initiative (GRI), which now has 50 pharmaceutical and biotech companies among its 1, 000-plus registered organisations.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...